ÂÜÀòÂÒÂ×

David Portman, MD, Sermonix CEO and chief medical officer, was a principal investigator for the phase 2 and 3 lasofoxifene trials and a consultant during drug development. Dr Portman has experience in all stages of the regulatory approval process and has worked with the FDA on numerous pre-approval and approval meetings, advisory committees, and submission and approval considerations. He has worked with the medical, marketing, launch, and sales aspects of many products in the women’s healthcare space.